Menu

Refunds Coming to Theranos’s Arizona Customers

The blood-testing startup settles a legal dispute with the Arizona attorney general’s office.

Apr 20, 2017
Bob Grant

WIKIMEDIA, JHEUSERA day after diagnostics company Theranos announced that it had reached a settlement with the Centers for Medicare and Medicaid Services (CMS) involving conditions at its blood-testing labs in California, the company said that it had resolved another legal battle. On Tuesday (April 18), Theranos said that would be returning more than $4.5 million to Arizona consumers, to reimburse them for blood-testing services they had purchased through the firm between 2013 and 2016.

“Everyone who paid for a test will receive a full refund, period,” Mark Brnovich, the Arizona attorney general who was pursuing legal action against Theranos—alleging that the company misrepresented the methodology, accuracy, and reliability of the diagnostic tests it was selling—said in a statement.  “This is a great result and a clear message that Arizona’s consumer protection laws will be vigorously enforced.”

Theranos also agreed to pay $200,000 in civil penalties to the state of Arizona and $25,000 in lawyer’s fees. Further, the firm will not operate any kind of laboratory in Arizona for a period of two years, backdated to March 28, 2017.

According to a statement released by Theranos, the company’s Arizona settlement “demonstrated the company’s commitment to resolving the issue amicably on behalf of Arizonans and working collaboratively with state officials.”

“With the agreement,” the statement continued, “both parties intend to resolve all existing or potential claims against Theranos, which settled the matter without any admission of liability.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.